Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 26

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 26
---
 The shares of common stock issuable upon exercise of the Prefunded Warrants, Series A Warrants and Series B Warrants held by Great Point Capital, LLC are each subject to a beneficial ownership limitation of 9.99% and accordingly, not all shares underlying such warrants are reflected in the table above as being beneficially owned.

(6) Reflects (i) 20,425 shares of common stock; (ii) 12,255 shares of common stock issuable upon the exercise of Series A common warrants to purchase shares of common stock issued in the May 2024 PIPE Financing (the “May 2024 Series A Warrants”); (iii) 12,255 shares of common stock issuable upon the exercise of May 2024 Series B Warrants; and (iv) 138,904 shares of common stock underlying options that are currently exercisable and unvested options to purchase shares of common stock held by Dr. Hedrick that will vest within 60 days of April 18, 2025. Dr. Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics. (7) Reflects (i) 9,815 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 4,902 shares of common stock issuable upon the exercise of May 2024 Series B Warrants; and (iv) 27,518 shares of common stock underlying options that are currently exercisable and unvested options to purchase shares of common stock held by Mr. Sims that will vest within 60 days of April 18, 2025. Mr. Sims is the Chief Financial Officer of Plus Therapeutics. (8) Reflects (i) 26,497 shares of common stock; (ii) 9,804 shares of common stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 9,804 shares of common stock issuable upon the exercise of May 2024 Series B Warrants; and (iv) 19,455 shares of common stock underlying options that are currently exercisable and unvested options to purchase shares of common stock held by Mr. Clowes that will vest within 60 days of April 18, 2025. Mr. Clowes is a director of Plus Therapeutics. (9) Reflects 19,455 shares of common stock underlying